Therefore, these results, as mentioned previously, indicate the efficacy of both brolucizumab and conbercept as novel VEGF inhibitors for the treatment of posterior segment eye diseases, especially AMD and DR, due to their longer duration of action and reduced need for injections. This evidence concerns the gene VEGFA and age-related macular degeneration.